Feline interferon-ω treatment on canine parvovirus infection
Introduction
Recombinant feline interferon-ω preparation (rFeIFN-ω, trade name: INTERCAT) had been approved as the first veterinary anti-viral agent for feline calicivirus infection in 1994 and also approved as a treatment agent for canine parvovirus infection in 1997 in Japan (Yamamoto et al., 1990, Shimoda et al., 1997). A well-controlled study was designed to confirm the efficacy of rFeIFN-ω on canine varvovirus infection with the use of beagles as well as field clinical studies.
Section snippets
Interferon
The rFeIFN-ω is a lyophilized preparation for injection and was supplied from Toray Industries, (Ueda et al., 1993). One vial contains 10 million units (MU) of recombinant Feline Interferon-ω and it was dissolved in 1 ml of physiological saline just before use.
Viruses
The pathogenic strain of canine parvovirus (CPV) used in this study was supplied by Drs. Masami Mochizuki and Nobuyoshi Ishiguro of Tsukuba Central Laboratories of Kyoritsu Shoji. The pathogenic potential of this strain was confirmed in a
Results and discussion
A total of 36 beagles about four months old in three groups were used: 12 for the 1 MU group, 7 for the 5 MU group, 17 for the control group. The beagles were inoculated orally with CPV-2 suspension (10 ml/head of 106TCID50/ml). Beagles in the 1 MU and 5 MU group were injected intervenously with 1 MU/kg and 5 MU/kg of rFeIFN-ω, respectively, once a day for three consecutive days starting four days after the CPV inoculation. Physiological saline was administered to the control group. The administration
References (4)
- et al.
In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours
Res. Vet. Sci.
(1995) - Shimoda, T., Uchino, T., Yamane, Y., Motoyoshi, S, 1997. Treatment effects of feline interferon on canine parvovirus...
Cited by (38)
Antiviral Chemotherapy and Immunomodulatory Drugs
2022, Greene's Infectious Diseases of the Dog and Cat, Fifth EditionThe Caliciviridae Family
2022, Encyclopedia of Infection and ImmunityInterferon therapies in small animals
2021, Veterinary JournalCitation Excerpt :In vitro, rFe IFN-ω inhibits CPV replication (Wang et al., 2020). In vivo, a number of studies have evaluated rFe IFN-ω for the treatment of canine parvoviral enteritis (Ishiwata et al., 1998; Minagawa et al., 1999; Martin et al., 2002; de Mari et al., 2003). All reported similar results (Table 7) and provide strong evidence to support the use of rFe IFN-ω in the treatment of canine parvoviral enteritis.
Update on Canine Parvoviral Enteritis
2020, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :The role of interferons as a possible antiviral therapy has been investigated for dogs with CPV enteritis. Recombinant feline omega-interferon (1–5 × 106 IU/kg/d IV for 3 days) has been shown to decrease the incidence of fever, vomiting, diarrhea, and mortality and to improve appetite.92–95 The drug is not currently approved for use in the United States, but is available for use in Europe and Australia.
Design, biological activity and signaling pathway of bovine consensus omega interferon expressed in Pichia pastoris
2019, Molecular ImmunologyCitation Excerpt :A single functional gene and at least two pseudogenes are present in human IFN-ω, but only a single pseudogene can be identified in mice IFN-ω (Hardy et al., 2004), while the IFN-ω family appears to have expanded in cats, which possess at least 10 variants on the basis of cDNA evidence (Hughes, 1995). IFN-ω has been approved as the veterinary antiviral agent for feline calicivirus infection and canine parvovirus infection (Minagawa et al., 1999; Vischer, 2006), as well as other disease (Domenech et al., 2011; Litzlbauer et al., 2014; Zetner et al., 2004). In bovine IFN-ω (BoIFN-ω), there are 24 potential IFN-ωs and at least 8 pseudogenes, which is significantly more compared with human and mouse IFN-ωs (Walker and Roberts, 2009).
Interferon-omega: Current status in clinical applications
2017, International ImmunopharmacologyCitation Excerpt :There are several therapies used to treat CPV infections; however, many of them have drawbacks [50]. Reports suggest that rIFN-ω has a significant therapeutic effect on CPV-infected dogs [97,98]. For instance, it improved parvoviral clinical signs (such as pyrexia, vomiting, anorexia, and diarrhea), and reduced severe parvoviral enteritis and mortality in CPV infections.